Survey
Quarterly Survey: Geographic Atrophy (GA) Treatments including Apellis' Syfovre and Iveric Bio's Izervay October 2023
Ticker(s): APLS, ISEE20 Retina Specialists completed the survey
How many patients with Geographic Atrophy (GA) does your practice manage?
How would you best describe your practice?
- Academic
- Community
- Private
Are you familiar with the cases of occlusive retinal vasculitis reported by the ASRS ReST committee on Saturday July 15th, 2023?
How many patients with Geographic Atrophy (GA) are in your practice?
- Foveal (# of pts)
- Extrafoveal (# of pts)
How many of your GA patients started Syfovre in the past 30 days?
How many of your GA patients discontinued Syfovre in the past 30 days?
How many of your GA patients do you expect to start Syfovre in the next 30 days?
How will the ASRS Research and Safety in Therapeutics (ReST) Committee Update on Adverse Event Reports Associated with Syfovre impact your use of Syfovre, if at all?
Please elaborate on the impact the report will have on your use of Syfovre moving forward? Please be specific.
How would you rate Syfovre on the following (where 1 is low and 5 is high)?
- Safety
- Efficacy
- Patient access
- Patient willingness to try
How would you rate Zimura on the following (where 1 is low and 5 is high)?
- Safety
- Efficacy
- Patient access
- Patient willingness to try
What are the key distinctions between Syfovre and Zimura in terms of their overall profile and outcomes? Please be specific.
On a scale 1-10 (where 1 is low and 10 is high) how excited are you for Syfovre in treating GA?
How many patients with Geographic Atrophy (GA) does your practice manage?
On a scale 1-10 (where 1 is low and 10 is high) how excited are you for Syfovre in treating GA?
On a scale 1-10 (where 1 is low and 10 is high) how excited are you for Izervey in treating GA?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
